INTRODUCTION
============

Endoscopic resection is being more frequently performed as an esophageal-sparing and minimally invasive treatment for superficial esophageal neoplasia \[[@b1-ce-2018-151],[@b2-ce-2018-151]\]. Endoscopic treatments have shown acceptable oncological outcomes, with a local recurrence rate reported to range from 0.3% to 11.5% \[[@b3-ce-2018-151]\]. In addition, recent technical advances in endoscopic submucosal dissection (ESD) are expected to further improve the survival of patients receiving such treatment by allowing for *en bloc* resection of lesions \[[@b4-ce-2018-151],[@b5-ce-2018-151]\].

Reducing the procedure time is the current major challenge in esophageal ESD. Esophageal squamous cell carcinoma progresses by intraepithelial spread, which requires extensive resection. Moreover, the operability of the endoscope is more limited in the esophagus than in the stomach, and perforation is more likely to cause a severe condition in the esophagus. Therefore, very careful endoscopic manipulation is required, necessitating a longer operative time. Causes of perforation include excessive insufflation or direct trauma to the muscle layer induced by energy devices. Since the thickness of the dilated esophageal wall during insufflation is only 3 to 4 mm, slight injury to the deeper layer can induce perforation; the patient's respiration or physical movements during the operation may also increase the risk of perforation.

Therefore, controlling body movements and respiratory fluctuations may help prevent this complication and shorten the procedure time. The effectiveness of anesthesia using propofol during esophageal ESD has been reported in previous studies \[[@b6-ce-2018-151]-[@b8-ce-2018-151]\], and the combination of propofol and dexmedetomidine hydrochloride represents a promising strategy for mitigating the risk of ESD-related complications and shortening the procedure time \[[@b9-ce-2018-151]\]. Some studies have shown the effectiveness of general anesthesia (GA) during gastric ESD \[[@b10-ce-2018-151]-[@b13-ce-2018-151]\]; however, no studies have described whether or not GA reduces the operative time in esophageal ESD.

We conducted a multi-center retrospective cohort study to investigate the hypothesis that esophageal ESD under GA would shorten the procedure time compared to ESD under deep sedation (DS) using midazolam and pentazocine. We also evaluated the incidence of complications. This study aimed to provide beneficial information to enable clinical physicians to perform esophageal ESD more safely.

MATERIALS AND METHODS
=====================

Patients
--------

This study had a three-center, retrospective cohort design. A total of 227 lesions in 198 consecutive patients who underwent ESD for superficial esophageal neoplasia at Southern-Tohoku General Hospital in Fukushima, Hyogo Prefectural Awaji Medical Center in Hyogo Prefecture, and Kitano Hospital in Osaka between April 2011 and November 2017 were included in the study.

Outcomes and survey items
-------------------------

The following outcomes were compared between patients who underwent the procedure under GA and those who received DS: the primary outcome was the ESD procedure time, and the secondary outcomes were the complications associated with ESD, i.e., perforation, postoperative hemorrhaging, and aspiration pneumonia, and complications associated with anesthesia. In addition, we isolated the following potential confounding factors from electrical medical records to secure the validity of the comparison: age, sex, body mass index (BMI), American Society of Anesthesiologists (ASA) physical status classification \[[@b14-ce-2018-151]\], site, diameter, and circumference of the lesion; resected diameter and circumference of the lumen; dissection speed; *en bloc* resection rate; number of devices used; and rate of use of the clip-with-line method. In the DS group, we evaluated the rate of unintended DS. Systolic blood pressure \<90 mm Hg was defined as hypotension, heart rate \<50 beats/min as bradycardia, respiratory rate \<8 breaths/min as bradypnea, and SpO~2~ \<90% as hypoxemia.

This study was approved by the ethics committees of all participating institutions and conducted in accordance with the 1975 Declaration of Helsinki.

ESD procedure
-------------

ESD was performed using a single-channel endoscope with a water jet system (GIF-Q260J; Olympus Medical Systems Co., Tokyo, Japan), with CO~2~ insufflation (UCR; Olympus Medical Systems). A Dual knife (KD-650Q; Olympus Medical Systems) was used for the procedure, and a Hook knife (KD260LR; Olympus Medical Systems) was added as needed.

Sodium hyaluronate (0.4%, MucoUp; Seikagaku Co., Tokyo, Japan) was locally injected into the submucosa using a 25-G injection needle (Needle Master; Olympus Medical Systems). Hemostatic graspers (Coagrasper; FD-411QR; Olympus Medical Systems) were used for preventive coagulation and intraoperative hemostasis of vessels. A VIO300D (ERBE Elektromedizin Gmbh, Tübingen, Germany) was used as the electrosurgery unit. In this study, all of the surgeons in each facility were Certified Surgeons of the Japanese Gastroenterological Endoscopy Society, each with experience performing more than 30 cases of esophageal ESD and more than 100 cases of gastric ESD.

The procedure time was defined as the time from the beginning of the submucosal injection to complete removal. The average dissection speed was calculated by dividing the time of the procedure by the area of the resected specimen, which was calculated as 3.14×0.25×long axis×minor axis. The procedure time included delays due to movement of the patient during the procedure.

Esophageal perforation was defined as macroscopic perforation to the esophageal wall, and postoperative hemorrhaging was defined as post-ESD hematemesis requiring an endoscopic procedure, bleeding accompanied by melena, anemia (decrease of ≥ hemoglobin 2 g/dL), or a condition requiring transfusion.

Deep sedation and general anesthesia
------------------------------------

In this study period, all patients were allocated to receive DS or GA during the operation, at the physician's discretion.

The principal of DS was established by the ASA \[[@b14-ce-2018-151]\]. In brief, an initial dose of 7.5 mg pentazocine and 2 mg midazolam for patients weighing \<50 kg or 3 mg midazolam for patients weighing ≥50 kg was administered. In response to patients' body movements, 1 mg midazolam or 7.5 mg pentazocine was additionally administered. After completing ESD, 0.5 mg flumazenil was administered to awaken the patients.

In the GA group, a propofol intravenous drip of 1--2 mg/ kg/min was administered, 3% sevoflurane was administered for tracheal intubation, and 0.6--0.9 mg/kg rocuronium was administered as a muscle relaxant. Intraoperative sevoflurane was maintained at 1%--1.5%, and 0.3--0.5 µg/kg/min remifentanil was administered as an adjuvant.

All agents were administered by a gastroenterologist who was not involved in the ESD procedure. Oxygen at 2 L/min was administered via a nasal cannula in the endoscopy room, and 3-lead electrocardiography, pulse oximetry, and automatic blood pressure monitoring were performed to monitor vital signs and oxygen saturation, with recordings made every 5 min.

Statistical analyses
--------------------

The chi-squared test, Kruskal-Wallis exact test, or Fisher's exact test were used to compare categorical variables. Continuous variables were expressed as median and range. Median values of continuous data were compared using the Mann-Whitney *U*-test. All statistical analyses were performed using the IBM SPSS software program (IBM Co., Armonk, NY, USA). All tests were two-tailed, and a *p*-value of \<0.05 was considered statistically significant.

RESULTS
=======

Patient characteristics
-----------------------

Patient characteristics are summarized in [Table 1](#t1-ce-2018-151){ref-type="table"}. Among 198 patients with esophageal neoplasia, ESD under GA was performed in 102 patients (51.5%), and ESD under DS was performed in 96 patients (48.5%). There were no significant differences in age, sex, BMI, comorbidities, or use of antithrombotic drugs between the GA and DS groups. Patients with a poorer ASA score were more common in the GA group than in the DS group.

Clinicopathological factors between the GA and DS group
-------------------------------------------------------

There were significant differences in the size of tumors (*p*\<0.001), tumor circumference of the lumen (*p*=0.042), and histologic type (*p*=0.030) between the groups. There were no significant differences in the location of tumors, depth of invasion, or lymphatic and vascular invasion ([Table 2](#t2-ce-2018-151){ref-type="table"}). Although there was no significant difference between the 2 groups in terms of the resected diameter, the GA group had a significantly higher proportion of patients with a lumen circumference ≥2/3 (*p*=0.005).

Procedure outcomes
------------------

[Table 3](#t3-ce-2018-151){ref-type="table"} shows the outcomes. The ESD procedure times for the GA and DS groups were 28 (5--202) and 40 (8--249) min, respectively (*p*\<0.001), indicating a significantly shorter procedure time in the GA group. There were no significant differences in the incidence of complications between the 2 groups. In the DS group, intraoperative perforation occurred in 2 patients (1.8%) and aspiration pneumonia occurred in 2 patients (1.8%). The perforation in 1 patient was not from trauma to the muscle layer caused by the knife but rather from a large rupture caused by intraoperative eructation. As the perforation was large and could not be sutured with clips, surgical drainage was performed. The other patient's perforation was induced by trauma to the muscle layer caused by a knife and was successfully sutured with clips. There were no marked differences in the *en bloc* resection rates between the 2 groups. The dissection speed was significantly higher in the GA group than in the DS group (*p*\<0.001). The number of patients who required the use of multiple devices was significantly higher in the DS group than in the GA group (*p*=0.001), but the rate of use of the clip-with-line method \[[@b15-ce-2018-151],[@b16-ce-2018-151]\] was comparable between the 2 groups.

In the DS group, the median total amount of midazolam was 10.8 (4.0--27.0) mg and the median total amount of pentazocine was 7.5 (0--30) mg. The median number and amount of bolus injections of midazolam were 2 (0--12) times and 2.0 (0--12) mg, respectively. The median number and amount of bolus injections of pentazocine were 0 (0--3) times and 0 (0--22.5) mg, respectively. The median frequency of body movement during ESD was 2 (0--14) times.

Safety evaluation
-----------------

There were no complications associated with GA and no mortalities among the enrolled patients. In the DS group, hypotension occurred in 7 patients (6.3%), bradycardia occurred in 5 patients (4.5%), hypoxemia occurred in 2 patients (1.8%), and bradypnea occurred in 3 patients (2.7%). No patients required assisted mask ventilation or intubation. A paradoxical response during sedation occurred in 3 patients (2.7%), but ESD was successfully completed under DS.

DISCUSSION
==========

In the present study, we compared the operative time and incidence of complications between the patients who underwent esophageal ESD under GA and those who received DS. Our results yielded 2 important findings. One is that the operative time of esophageal ESD with GA was shorter than that of ESD with DS. The other is that there were no significant differences in the incidence of all types of complications related to ESD or sedation between the 2 groups. The GA group had a higher proportion of patients with a larger lumen circumference of the lesion. Therefore, these results suggest that operators tend to choose GA when treating difficult cases. Even though difficult cases were more common in the GA group, the procedure time in the GA group was ultimately shorter than that in the DS group, and the dissection speed was faster as well. This reflects the effect of a reduced procedure time by GA. In addition, there were no complications associated with GA among the enrolled patients.

Among several reports that have described the methods of anesthesia for esophageal ESD, one study reported that the combination of propofol and dexmedetomidine hydrochloride shortened the esophageal ESD procedure time significantly compared to midazolam or flunitrazepam \[[@b9-ce-2018-151]\], as this combination was able to suppress the patients' body movements during the procedure. The major point of emphasis in the present study is that GA can completely suppress patients' body movements and stabilize their respiratory fluctuations and heartbeat. We believe that these effects of GA represent a significant advantage with regard to ensuring the safety of esophageal ESD.

However, another previous study reported results contrary to those of our study, with the procedure time on using non-GA being shorter than that of procedures using GA \[[@b13-ce-2018-151]\]. That study also reported that the proportion of non-expert operators performing ESD under GA was significantly higher than that of those performing ESD under DS, which may represent a major confounding factor in their results. In the present study, interoperator differences were controlled, as all of the surgeons in this study were experts with experience in managing over 100 cases of gastric ESD and 30 cases of esophageal ESD, thereby precluding such confounding.

There were no significant differences between the 2 groups in terms of the 3 complications of perforations, hemorrhaging, and aspiration pneumonia, which were the secondary outcomes of this study. This result may be due to the low incidence of complications overall (GA group: 2 patients; DS group: 4 patients) and the small sample size. Indeed, the higher number of perforations in the DS group could have been prevented by controlling body movements, respiratory changes, and eructation. Aspiration pneumonia occurred in the DS group. Previous reports have also indicated that gastric ESD under conscious sedation is a risk factor for pulmonary aspiration \[[@b17-ce-2018-151],[@b18-ce-2018-151]\]; therefore, airway management and positive-pressure ventilation may be effective measures for preventing these complications. Conversely, there were more patients with postoperative hemorrhaging in the GA group than in the DS group. However, analysis according to the patients' background characteristics suggested that the GA group was at higher risk of hemorrhaging simply because they had higher numbers of large lesions and required a larger extent of resection.

One of the limitations of this study was the determination of the outcomes. Complications in esophageal ESD are quite rare, with rates of 0%--6.9% for intraoperative perforations and 1.6%--6.6% for aspiration pneumonia \[[@b1-ce-2018-151],[@b2-ce-2018-151],[@b4-ce-2018-151],[@b5-ce-2018-151],[@b8-ce-2018-151],[@b19-ce-2018-151]\]. If we had selected the complications as the primary outcome, the analyses would have had insufficient statistical power. Therefore, we set the operative time as a surrogate endpoint in this study. Another associated limitation is that the allocation of patients to the GA or DS groups was decided at the physicians' discretion, so there may be some residual confounding. However, as mentioned above, given that the GA group included more patients with more difficult-to-treat lesions, the results demonstrating a shortened procedure time in the GA group with no marked differences in complications are decidedly noteworthy. Further studies are needed to compare dexmedetomidine or propofol with GA. In addition, future studies should evaluate the satisfaction among endoscopists and patients according to the sedation method and the speed of recovery.

In conclusion, esophageal ESD under GA is associated with a shortened ESD procedure time compared to ESD under DS.
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###### 

Baseline Characteristics of the Patients in the Two Groups

                             General anesthesia (*n*=102)   Deep sedation (*n*=96)   *p*-value
  -------------------------- ------------------------------ ------------------------ -----------
  Age (yr)                   70 (50--87)                    69 (43--82)              0.183
  Sex                                                                                \>0.999
   Male                      89 (87.3)                      83 (86.5)                
   Female                    13 (12.7)                      13 (13.5)                
  BMI (kg/m^2^)              22.5 (11.3--28.1)              21.3 (14.6--32.3)        0.397
  ASA score                                                                          0.018
   I                         30 (29.4)                      19 (19.8)                
   II                        67 (65.7)                      77 (80.2)                
   III                       5 (4.9)                        0                        
  Comorbidity                                                                        
   Hypertension              52 (51.0)                      45 (46.9)                0.573
   Hyperlipidemia            13 (12.7)                      15 (15.6)                0.684
   Diabetes mellitus         15 (14.7)                      13 (13.5)                0.841
   Chronic kidney diseases   3 (2.9)                        0                        0.247
   Chronic liver diseases    4 (3.9)                        9 (9.4)                  0.155
  Antithrombotic drugs       26 (25.5)                      19 (19.8)                0.397

Values are expressed as median (range) or *n* (%).

ASA, American Society of Anesthesiologists; BMI, body mass index.

###### 

Clinicopathological Factors between General Anesthesia and Deep Sedation

                                       General anesthesia (*n*=115)   Deep sedation (*n*=112)   *p*-value
  ------------------------------------ ------------------------------ ------------------------- -----------
  Size of tumors (mm)                  21 (3--77)                     14 (3--63)                \<0.001
  Location of tumors                                                                            0.05
   Upper third                         22 (19.1)                      11 (9.8)                  
   Middle third                        67 (58.3)                      63 (56.3)                 
   Lower third                         26 (22.6)                      38 (33.9)                 
  Circumference of the lumen (tumor)                                                            0.042
   \<2/3                               99 (86.1)                      106 (94.6)                
   ≥2/3                                16 (13.9)                      6 (5.4)                   
  Histologic type                                                                               0.03
   Squamous cell carcinoma             98 (85.2)                      108 (96.4)                
   Intraepithelial neoplasia           9 (7.8)                        3 (2.7)                   
   Adenocarcinoma                      7 (6.1)                        1 (0.9)                   
   Others                              1 (0.9)                        0                         
  Depth of invasion                                                                             0.105
   EP                                  57 (49.6)                      47 (42.0)                 
   LPM                                 25 (21.7)                      40 (35.7)                 
   MM                                  19 (16.5)                      17 (15.2)                 
   SM                                  14 (12.2)                      8 (7.1)                   
  Lymphatic invasion                   5 (4.3)                        2 (1.8)                   0.446
  Vascular invasion                    3 (2.6)                        0                         0.247

Values are expressed as median (range) or *n* (%).

EP, epithelium; LPM, lamina propria mucosae; MM, muscularis mucosae; SM, submucosa.

###### 

Procedure Outcomes and Adverse Events

                                                 General anesthesia (*n*=115)   Deep sedation (*n*=112)   *p*-value
  ---------------------------------------------- ------------------------------ ------------------------- -----------
  Size of resected specimen, (mm)                35 (12--90)                    32 (10--77)               0.129
  Circumference of resected ulcer of the lumen                                                            0.005
   \<2/3                                         86 (74.8)                      96 (85.7)                 
   ≥2/3                                          29 (25.2)                      16 (14.3)                 
  *En bloc* resection rate                       115 (100)                      110 (98.2)                0.242
  Procedure time (min)                           28 (5--202)                    40 (8--249)               \<0.001
  Submucosal dissection speed (mm^2^/min)        25.2 (7.8--157.2)              16.2 (2.4--41.3)          \<0.001
  Single device                                  115 (100)                      102 (91.1)                0.001
  Clip-with-line method                          19 (16.5)                      28 (25.0)                 0.141
  Delayed bleeding                               2 (1.7)                        0                         0.498
  Intraoperative perforation                     0                              2 (1.8)                   0.242
  Aspiration pneumonia                           0                              2 (1.8)                   0.242
  Stenosis                                       9 (7.8)                        8 (7.1)                   1
  Odontoclasis                                   0                              0                         \-
  Anaphylaxis                                    0                              0                         \-
  Thromboembolism                                0                              0                         \-
  Tracheobronchial injury                        0                              0                         \-
  Mortality                                      0                              0                         \-

Values are expressed as median (range) or *n* (%).
